Biogen (BIIB) Common Equity (2009 - 2026)

Biogen's Common Equity history runs 18 years deep, the most recent figure standing at $18.7 billion for Q1 2026.

• In Q1 2026, Common Equity rose 9.85% year-over-year to $18.7 billion; the TTM figure through Mar 2026 stood at $18.7 billion (up 9.85% YoY), while the FY2025 annual figure was $18.3 billion, up 9.22% from the prior year.
• Common Equity was $18.7 billion for Q1 2026 at Biogen, up from $18.3 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $18.7 billion in Q1 2026 to a low of -$171.2 million in Q3 2025.
• Historically, Common Equity has averaged $14.3 billion across 5 years, with a median of $14.8 billion in 2023.
• The sharpest annual moves came in 2023 and 2025: Common Equity climbed 22.87% in 2023, then tumbled 101.05% in 2025.
• A 5-year view of Common Equity shows it stood at $13.4 billion in 2022, then increased by 10.54% to $14.8 billion in 2023, then grew by 12.95% to $16.7 billion in 2024, then rose by 9.22% to $18.3 billion in 2025, then gained by 2.16% to $18.7 billion in 2026.
• The last three Common Equity figures came in at $18.7 billion (Q1 2026), $18.3 billion (Q4 2025), and -$171.2 million (Q3 2025), per Business Quant data.